THRD (Third Harmonic Bio) Forward P/E Multiple
Third Harmonic Bio focuses on developing oral treatments for immune pathologies, expecting profits from the commercialization of selective inhibitors. The issuer's forward P/E illustrates the asset valuation trend, where the 0.00 level indicates the parameter's status. Successes of THB001 in urticaria therapy are driving growth, and upcoming mid-stage test results will serve as catalysts despite current R&D expenditures.
Analytical breakdowns for Third Harmonic Bio
- current price and projected stock value:
- business market valuation indicators:
- book capitalization information:
- debt and liquidity details:
Total Debt to Equity Ratio Third Harmonic Bio|THRD - Long-Term Debt to Capital|Short-Term Debt to Equity Third Harmonic Bio|THRD - Company Aggregate Debt|Debts to Book Capitalization Third Harmonic Bio Inc.|THRD - Long-Term Debt|Company Current Liabilities Third Harmonic Bio|Quick Ratio thirdharmonicbio.com
- company profitability and valuation multiples indicators:
THRD - Final Profit|Projected Future Earnings Third Harmonic Bio|THRD - Business Payback Period|Future Price to Earnings Third Harmonic Bio, Inc|THRD - Growth-Adjusted Payback Ratio|EV/EBITDA Multiple Third Harmonic Bio Inc.|THRD - Operating profit before amortization|Net earnings per share for the last 12 months Third Harmonic Bio|THRD - Earnings per share for the trailing year|Quarterly EPS earnings growth thirdharmonicbio.com|THRD - Earnings per share increase in current year|Earnings growth forecast for next year Third Harmonic Bio
Summary company analytics:Third Harmonic Bio, Inc.
Forward P/E reflects the market value of future earnings, allowing for an assessment of the degree of investor optimism regarding profit growth rates already priced in. Since the success of Third Harmonic Bio (THRD) depends on clinical trial results within the defensive immunology sector, the company's forward P/E multiple serves as an indicator of market confidence in the issuer's scientific progress, determining the fair balance between risk and capital.
Competitors of Third Harmonic Bio (THRD)
Projected Price to Earnings ARGX (argenx)|BNTX (BioNTech Inc.) - Future Price to Earnings Multiple|Forward P/E Multiple ABVX (abivax.com)|Market Cap to Projected Earnings ADMA Corp (ADMA)|PTGX - Future Price to Earnings|immunovant.com (IMVT) - Projected Price to Earnings|Kiniksa (KNSA) - Future Price to Earnings|Projected Price to Earnings Grifols SA|Projected Price to Earnings ADPT|Forward P/E Multiple Celldex Corp|Future Price to Earnings Aurinia Pharmaceuticals (AUPH)|biocryst.com - Price to Future Earnings Ratio|Forward P/E Multiple VERA (Vera Therapeutics)|Dianthus Therapeutics Inc (DNTH) - Projected Price to Earnings Ratio|PHVS: Projected Price to Earnings|AbCellera Biologics - Market Cap to Future Earnings Ratio|TRML: Forward P/E Multiple|precigen.com - Future Price to Earnings Multiple|PHAR (Pharming Group) - Forward P/E Multiple|Nektar Therapeutics Inc (NKTR) - Market Cap to Projected Earnings|Future Price to Earnings Upstream Bio Corp (UPB)|ZBIO (Zenas Corp) - Future Price to Earnings Multiple|Forward P/E Multiple IMNM (Immunome, Inc.)|GOSS: Price to Future Earnings Ratio|KALV: Projected Price to Earnings|Future Price to Earnings Multiple SEPN (Septerna, Inc.)|PVLA: Forward P/E Multiple|Savara Pharma - Future Price to Earnings Multiple|RIGL (Rigel Pharmaceuticals) - Forward P/E Multiple|Forward P/E Multiple anaptysbio.com|Future Price to Earnings Astria Therapeutics, Inc. (ATXS)|ENGN (enGene Holdings Inc) - Future Price to Earnings Multiple|Future Price to Earnings RAPT Therapeutics, Inc. RAPT|JBIO - Projected Price to Earnings|ACRS - Future Price to Earnings|Projected Price to Earnings Ratio kyvernatx.com|Tiziana Life Sciences Ltd (TLSA) - Future Price to Earnings|Price to Future Earnings Ratio CABA|VTYX (Ventyx Bio) - Forward P/E Multiple|Theratechnologies, Inc (THTX) - Market Cap to Projected Earnings|Forward P/E Multiple AVTX|Projected Price to Earnings eledon.com ELDN|Agenus Inc. - Projected Price to Earnings|Future Price to Earnings Multiple CLYM|Zura Bio Limited - Forward P/E Multiple|ATYR: Future Price to Earnings|ADAG: Forward P/E Multiple|IMA - Market Cap to Projected Earnings|Future Price to Earnings Shattuck Labs Inc|Projected Price to Earnings Ratio Equillium Bio EQ|Projected Price to Earnings CNTB (Connect Biopharma)|Market Cap to Future Earnings Ratio IMUX|Forward P/E Multiple ATRA (Atara Bio)|Future Price to Earnings Multiple IFRX|XFOR - Future Price to Earnings|Future Price to Earnings Multiple ACET (Adicet Bio)|CELU: Forward P/E Multiple|Price to Future Earnings Ratio INMB|Future Price to Earnings Barinthus Biotherapeutics|kezarlifesciences.com - Price to Expected Earnings Ratio|Forward P/E Multiple SABS|AKTX (Akari Therapeutics PLC) - Future Price to Earnings Multiple|Forward P/E Multiple ENLV (Enlivex Therapeutics Ltd.)|Forward P/E Multiple Q32 Bio Inc QTTB|GOVX - Future Price to Earnings|Future Price to Earnings Multiple EDSA (edesabiotech.com)|iBio (IBIO) - Future Price to Earnings|Projected Price to Earnings Carisma Therapeutics Inc.|XTLB (XTL Biopharmaceuticals, Ltd.) - Forward P/E Multiple|Forward P/E Multiple Bolt Bio|Projected Price to Earnings HCWB (HCW Biologics Inc.)|APVO (aptevotherapeutics.com) - Future Price to Earnings Multiple|Forward P/E Multiple AIM (AIM ImmunoTech)|Market Cap to Projected Earnings Aditxt Inc. (ADTX)|GRI - Future Price to Earnings|XORTX Corp (XRTX) - Projected Price to Earnings|Vyome Holdings Inc (HIND) - Future Price to Earnings|Projected Price to Earnings revbiosciences.com|Projected Price to Earnings INDP|Forward P/E Multiple Scinai Immunotherapeutics Ltd|Future Price to Earnings CalciMedica, Inc. (CALI)|affimed.com - Price to Future Earnings Ratio|Forward P/E Multiple ALLK (Allakos)|HOOKIPA Pharma, Inc. (HOOK) - Projected Price to Earnings Ratio|IGMS: Projected Price to Earnings|iTeos Therapeutics Inc - Market Cap to Future Earnings Ratio|OCEA: Forward P/E Multiple|TC BioPharm Ltd - Future Price to Earnings Multiple
